. Author manuscript; available in PMC: 2014 Jan 7.

Published in final edited form as: Gynecol Oncol. 2012 Apr 6;126(1):10.1016/j.ygyno.2012.03.049. doi: 10.1016/j.ygyno.2012.03.049

Table-2. EC₅₀ values of Taxol.

A: First generation Taxol-r8 conjugates

	EC50 (μM)
Patient	Taxol	2a	3a
A ascites^*	⋙20	1.4	1.3
B ascites	⋙20	7.7	4.6
C ascites	⋙20	15	11
D ascites^‡	⋙20	17	24
E ascites^†,^‡	⋙20	14	17
F ascites^*	⋙20	4.2	4.4
G ascites^*^,^§	⋙20	1.2	---
H ascites^†,^¶	⋙20	21	---
I solid tumor^†	16.2	3.9	3.1

B: Second generation Taxol-r8 conjugates

	EC₅₀ (μM)
Patient	2b	2c	2d	3b	3c	3d

A ascites^*	1.0	---	---	2.2	---	1.1
B ascites	8.0	---	---	1.2	---	---
F ascites^*	3.4	4.2	2.3	3.7	1.5	1.0
G ascites^*^,^§	1.5	3.7	2.3	2.5	4.3	1.5
H ascites^†,^¶	23.0	---	---	---	20.0	---

Refer to Figure 1 for chemical structures of Taxol-r8 conjugates (2a, 3a) and (2b, 2c, 2d, 3b, 3c, and 3d)

Values calculated from 5 different compound concentrations ranging from 0.625 μM to 20 μM

Results are the mean of two independent experiments

^‡

48-hr incubation.

^§

Clear cell carcinoma.

^¶

Carcinosarcoma

Table-2. EC50 values of Taxol.